Clinical trial
Weekly Bendamustine and Bortezomib Combination Therapy in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or B-CLL: A Single-Center Phase 2 Study
NCT00426855 is registered in ClinicalTrials.gov with Peter Moosmann as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Weekly Bendamustine and Bortezomib Combination Therapy in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or B-CLL: A Single-Center Phase 2 Study
- Lead sponsor
- Peter Moosmann
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- January 31, 2007
- Completion date
- June 30, 2009
- Enrollment
- 12 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.